GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Natco Pharma Ltd (BOM:524816) » Definitions » EPS (Diluted)

Natco Pharma (BOM:524816) EPS (Diluted) : ₹77.30 (TTM As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Natco Pharma EPS (Diluted)?

Natco Pharma's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was ₹21.56. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹77.30.

Natco Pharma's EPS (Basic) for the three months ended in Mar. 2024 was ₹21.56. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹77.30.

Natco Pharma's EPS without NRI for the three months ended in Mar. 2024 was ₹21.56. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was ₹77.30.

During the past 12 months, Natco Pharma's average EPS without NRIGrowth Rate was 97.40% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 49.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 13.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 16.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Natco Pharma's highest 3-Year average EPS without NRI Growth Rate was 65.30% per year. The lowest was -38.00% per year. And the median was 16.50% per year.


Natco Pharma EPS (Diluted) Historical Data

The historical data trend for Natco Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Natco Pharma EPS (Diluted) Chart

Natco Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.26 24.16 9.32 39.18 77.34

Natco Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.10 23.26 20.60 11.88 21.56

Competitive Comparison of Natco Pharma's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Natco Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Natco Pharma's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Natco Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Natco Pharma's PE Ratio falls into.



Natco Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Natco Pharma's Diluted EPS for the fiscal year that ended in Mar. 2024 is calculated as

Diluted EPS (A: Mar. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(13883-0)/179.506
=77.34

Natco Pharma's Diluted EPS for the quarter that ended in Mar. 2024 is calculated as

Diluted EPS (Q: Mar. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(3863-0)/179.121
=21.57

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹77.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Natco Pharma  (BOM:524816) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Natco Pharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Natco Pharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Natco Pharma (BOM:524816) Business Description

Traded in Other Exchanges
Address
Road No. 2, NATCO House, Banjara Hills, Hyderabad, TG, IND, 500034
Natco Pharma Ltd is a major drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. Within the pharma business segment, the company drives its sales through Finished Dosage Forms and Active Pharmaceutical Ingredients.

Natco Pharma (BOM:524816) Headlines

No Headlines